300552-38-9

Basic information

• Product Name: SPIRO[2H-1-BENZOPYRAN-2,4'-PIPERIDIN]-4(3H)-ONE, 6-CHLORO-, HYDROCHLORIDE
• Synonyms: SPIRO[2H-1-BENZOPYRAN-2,4'-PIPERIDIN]-4(3H)-ONE, 6-CHLORO-, HYDROCHLORIDE;Spiro-6-chloro-[2H-1-benzopyran-2,4'-piperidin]-4(3H)-one;6-Chlorospiro[chroMan-2,4'-piperidin]-4-one hydrochloride;6-chloro-3,4-dihydrospiro[1-benzopyran-2,4'- piperidine]-4-one;Spiro[2h-1-benzopyran-2,4'-piperidin]-4(3h)-one, 6-chloro-, HCl;6-chlorospiro[chromane-2,4-piperidin]-4-one hydrochloride
• CAS NO: 300552-38-9
• Molecular Formula: C13H15Cl2NO2
• Molecular Weight: 288.18
• Mol File: 300552-38-9.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 448.4 °C at 760 mmHg
• Flash Point: 225 °C
• Appearance: /
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: SPIRO[2H-1-BENZOPYRAN-2,4'-PIPERIDIN]-4(3H)-ONE, 6-CHLORO-, HYDROCHLORIDE(CAS DataBase Reference)
• NIST Chemistry Reference: SPIRO[2H-1-BENZOPYRAN-2,4'-PIPERIDIN]-4(3H)-ONE, 6-CHLORO-, HYDROCHLORIDE(300552-38-9)
• EPA Substance Registry System: SPIRO[2H-1-BENZOPYRAN-2,4'-PIPERIDIN]-4(3H)-ONE, 6-CHLORO-, HYDROCHLORIDE(300552-38-9)

Safety Data

• Hazardous Substances Data: 300552-38-9(Hazardous Substances Data)

Usage

General Description

SPIRO[2H-1-BENZOPYRAN-2,4'-PIERIDIN]-4(3H)-ONE, 6-CHLORO-, HYDROCHLORIDE is a chemical compound with potential pharmaceutical properties. It is a synthetic derivative of the natural compound spirooxindole and has been studied for its potential therapeutic effects, particularly in the treatment of cancer. SPIRO[2H-1-BENZOPYRAN-2,4'-PIPERIDIN]-4(3H)-ONE, 6-CHLORO-, HYDROCHLORIDE has been found to exhibit cytotoxicity against various cancer cell lines, making it a promising candidate for further development as a potential anticancer agent. The hydrochloride salt form of this compound is commonly used to improve its solubility and stability, which can be beneficial for pharmaceutical applications. Overall, this compound shows potential as a novel drug candidate for the treatment of cancer and warrants further exploration in preclinical and clinical studies.

Upstream product

• 50893-53-3 carbonochloridic acid 1-chloro-ethyl ester 
• 81122-68-1 1'-benzyl-6-chlorospiro[chromene-2,4'-piperidin]-4(3H)-one 
• 1011482-37-3 N-Boc-6-chlorospiro[chromene-2,4'-piperidin]-4(3H)-one 
• 1450-74-4 5-chloro-2-hydroxyacetophenone 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 

Relevant articles and documents

Design, Synthesis, and Structure-Activity Relationship of Novel Spiropyrimidinamines as Fungicides against Pseudoperonospora cubensis

Harmful fungus and the developed resistance to available fungicides seriously threaten the yield and quality of crops; thus, the search for new, highly efficient, and resistance-overcoming fungicides remains a quite urgent goal of agricultural scientists. In this study, a series of novel spiropyrimidinamine derivatives were designed and synthesized by employing the intermediate derivatization method (IDM). Their structures were identified by 1H NMR, elemental analyses, and MS spectra. The structure of compound 5 was further confirmed by X-ray diffraction. Bioassays indicated that a number of the title compounds exhibited some fungicidal activities against Pseudoperonospora cubensis. Especially, compound 5 displayed excellent activity (EC50 = 0.422 mg/L), significantly higher than those of the commercialized fungicides cyazofamid, flumorph, and diflumetorim. The structure-activity relationship was also discussed. It was concluded that compound 5 with super fungicidal potency and a novel structure is a promising agrochemical fungicide candidate for further development.

Sorbitol dehydrogenase inhibitors

This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, wherein R1, R2and R3are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.